Canada markets open in 6 hours 44 minutes

Almirall SA (E2Z.SG)

Stuttgart - Stuttgart Delayed Price. Currency in EUR
Add to watchlist
8.33-0.34 (-3.92%)
As of 08:01AM CEST. Market open.
Full screen
Previous Close8.67
Open8.33
Bid8.65 x 1000000
Ask8.71 x 1000000
Day's Range8.33 - 8.33
52 Week Range7.11 - 9.97
Volume0
Avg. Volume0
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Investing.com

    Almirall's Ebglyss poised for EU approval, challenging Sanofi and Regeneron’s Dupixent

    Almirall, the Spanish pharmaceutical company, is on the brink of securing European Union (EU) approval for its IL-13 inhibitor lebrikizumab, marketed as Ebglyss, for atopic dermatitis treatment. The European Medicines Agency's (EMA) human medicines committee has recommended the drug's approval, setting up a challenge to the market-leading Dupixent, produced by Sanofi (NASDAQ:SNY) and Regeneron (NASDAQ:REGN).